Triamcinolone acetonide sustained release - Flexion Therapeutics
Alternative Names: FX-006; Triamcinolone acetonide extended release - Flexion Therapeutics; Triamcinolone acetonide, extended release injectable suspension - Flexion Therapeutics; Triamcinolone Acetonide, Immediate Release (TCA-IR) - Flexion Therapeutics; ZilrettaLatest Information Update: 26 May 2025
At a glance
- Originator Flexion Therapeutics
- Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Musculoskeletal pain
- Phase II Periarthritis
Most Recent Events
- 18 May 2025 Pacira Pharmaceuticals plans a phase II trial for Osteoarthritis in the US in June 2025 (Intra-articular) (NCT06977568)
- 31 Dec 2023 Flexion Therapeutics has patent protection for ZILRETTA in USA
- 31 Dec 2023 Flexion Therapeutics has patents pending for ZILRETTA to treat OA pain in subpopulations of diabetic patients